CorMedix Inc. (CRMD) Short Interest Update

CorMedix Inc. (NYSEAMERICAN:CRMD) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 4,692,803 shares, a growth of 8.3% from the January 12th total of 4,332,544 shares. Approximately 7.6% of the company’s shares are sold short. Based on an average daily volume of 651,504 shares, the short-interest ratio is presently 7.2 days.

Separately, HC Wainwright set a $4.00 price target on CorMedix and gave the stock a “buy” rating in a research note on Monday, October 16th.

CorMedix (NYSEAMERICAN:CRMD) traded down $0.02 during trading on Friday, hitting $0.44. The stock had a trading volume of 807,128 shares, compared to its average volume of 702,847. CorMedix has a 1-year low of $0.32 and a 1-year high of $2.48. The stock has a market capitalization of $31.16, a price-to-earnings ratio of -0.72 and a beta of 0.18.

In other news, Director Steven W. Lefkowitz purchased 135,416 shares of the firm’s stock in a transaction on Tuesday, December 12th. The shares were bought at an average cost of $0.48 per share, for a total transaction of $64,999.68. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Khoso Baluch purchased 104,166 shares of the firm’s stock in a transaction on Tuesday, December 12th. The shares were purchased at an average price of $0.48 per share, for a total transaction of $49,999.68. Following the completion of the purchase, the chief executive officer now directly owns 225,373 shares of the company’s stock, valued at $108,179.04. The disclosure for this purchase can be found here. Insiders have acquired 312,498 shares of company stock worth $149,999 over the last 90 days.

Several institutional investors have recently bought and sold shares of CRMD. Sabby Management LLC purchased a new stake in shares of CorMedix during the second quarter worth $1,818,000. Susquehanna International Group LLP increased its position in shares of CorMedix by 11,785.4% during the second quarter. Susquehanna International Group LLP now owns 2,067,973 shares of the biotechnology company’s stock worth $886,000 after acquiring an additional 2,085,670 shares during the period. Spinnaker Capital LLC purchased a new stake in shares of CorMedix during the fourth quarter worth $202,000. Virtu Financial LLC increased its position in shares of CorMedix by 126.4% during the fourth quarter. Virtu Financial LLC now owns 226,748 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 126,610 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of CorMedix by 3.0% during the second quarter. Vanguard Group Inc. now owns 1,208,894 shares of the biotechnology company’s stock worth $518,000 after acquiring an additional 35,148 shares during the period.

TRADEMARK VIOLATION WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/02/09/cormedix-inc-crmd-short-interest-update.html.

About CorMedix

CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply